Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Hepatitis C Infection With HIV Co-Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

Trial Locations (4)

Berlin

Bonn

Frankfurt am Main

London